Literature DB >> 18397298

Prolonged neurophysiologic effects of levetiracetam after oral administration in humans.

Charles M Epstein1, Lhys Girard-Siqueira, Joshua Andrew Ehrenberg.   

Abstract

PURPOSE: To determine whether neurophysiological effects of levetiracetam (LEV) outlast its serum half-life of approximately 7 h. Demonstration of prolonged effects would help to explain the efficacy of LEV at conventional dosing intervals that are longer than the serum half-life.
METHODS: Following an oral dose of LEV 3 g in 12 normal volunteers, we compared transcranial magnetic stimulation (TMS) measures of motor threshold (MT) and recruitment with LEV serum levels and subjective ratings of toxicity over 48 h. Subjects used a two-dimensional visual-analog scale to estimate the time course of any side effects.
RESULTS: LEV serum levels and subjective toxicity both peaked around 1 h after oral administration. MT elevation was delayed in comparison to peak serum levels and subjective toxicity. MT was maximally elevated at 6-9 h, and recruitment maximally reduced at 0.6-9 h. Changes in both measures had recovered by approximately 50% at 24 h. Despite the time difference between toxicity and TMS changes, toxicity estimates correlated with the maximum increase in MT.
CONCLUSION: There is a substantial time lag between LEV serum levels and TMS measures of neuronal effects, and a similar temporal dissociation between subjective toxicity and maximum TMS change. The time course of neurophysiological effects, as measured by TMS, may help to explain the sustained clinical efficacy of LEV despite a short peripheral half-life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397298     DOI: 10.1111/j.1528-1167.2008.01562.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.

Authors:  Nicholas S Abend; Heather M Monk; Daniel J Licht; Dennis J Dlugos
Journal:  Pediatr Crit Care Med       Date:  2009-07       Impact factor: 3.624

2.  Transcranial magnetic stimulation in Clinical Pharmacology.

Authors:  Dimitrios Kapogiannis; Eric M Wassermann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2008-12

3.  Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double-blind, placebo-controlled, cross-over study.

Authors:  Titia Q Ruijs; Jules A A C Heuberger; Annika A de Goede; Dimitrios Ziagkos; Marije E Otto; Robert J Doll; Michel J A M van Putten; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2022-02-03       Impact factor: 3.716

4.  The Effect of Lamotrigine and Levetiracetam on TMS-Evoked EEG Responses Depends on Stimulation Intensity.

Authors:  Isabella Premoli; Alyssa Costantini; Davide Rivolta; Andrea Biondi; Mark P Richardson
Journal:  Front Neurosci       Date:  2017-10-20       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.